SCHEMBL5770489

SCHEMBL5770489

O=C(NC[C@@H]1NCCc2c1sc(NC(=O)C(=O)O)c2C(=O)O)Nc1ccc(Oc2ccccc2)cc1

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 10/20 0.55
MAPT P10636 2/20 0.44
MEN1 O00255 1/20 0.44
HTT P42858 1/20 0.44
KMT2A Q03164 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
ALDH1A1 P00352 1/20 0.41
PTPN2 P17706 6/20 0.39
PTPRC P08575 1/20 0.39
PTPRB P23467 1/20 0.39
PIN1 Q13526 1/20 0.38
EPHX1 P07099 1/20 0.37
CHRM4 P08173 1/20 0.37
MCHR2 Q969V1 1/20 0.37
MCHR1 Q99705 1/20 0.37
NAMPT P43490 1/20 0.37
RAB9A P51151 1/20 0.36
EPHX2 P34913 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5773123 0.85 PTPN1 (0.58) PTPN1MAPTMEN1HTTKMT2A
SCHEMBL5769588 0.84 PTPN1 (0.59) PTPN1MEN1KMT2ARAB9A
SCHEMBL5769105 0.83 PTPN1 (0.59) PTPN1MAPTMEN1KMT2ASMN1; SMN2
SCHEMBL5770525 0.82 PTPN1 (0.65) PTPN1MAPTMEN1KMT2ASMN1; SMN2
SCHEMBL7520290 0.80 PTPN1 (0.56) PTPN1PTPN2PTPRCPTPRB
SCHEMBL7513118 0.80 PTPN1 (0.41) PTPN1PTPN2PTPRCPTPRBPIN1
SCHEMBL5771521 0.79 PTPN1 (0.61) PTPN1MAPTSMN1; SMN2PTPN2PTPRC
SCHEMBL5838046 0.79 PTPN1 (0.46) PTPN1MAPTMEN1HTTKMT2A
SCHEMBL5768909 0.79 PTPN1 (0.62) PTPN1PTPN2PTPRCPTPRB
SCHEMBL5770158 0.79 PTPN1 (0.63) PTPN1PTPN2PTPRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1301516-B1 MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPASES) NOVO NORDISK AS (DK) 2006-03-22 EP disclosed
US-6613903-B2 Such as 7-(benzoylamino-methyl)-2-(oxalyl-amino)-4,5,6,7-tetrahydro-thieno(2,3 -c)pyridine-3-carboxylic acid for treatment of diabetes, insulin resistance, and obesity NOVO NORDISK A/S (DK) 2003-09-02 US disclosed
EP-1301516-A1 MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPASES) NOVO NORDISK A/S (DK) 2003-04-16 EP disclosed
US-20020151561-A1 Modulators of Protein Tyrosine Phosphatases (PTPases) NOVO NORDISK A/S (DK) 2002-10-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020151561-A1 Modulators of Protein Tyrosine Phosphatases (PTPases) PTPRO, PTPN1, PTPRS PTPN1 2/4885MAPT 4142/4885MEN1 4755/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.